ROCKVILLE, Md., Sept. 23, 2004 (PRIMEZONE) -- Cytomedix, Inc. (OTCBB:CYME) today announced it is scheduled to make a presentation on Wednesday, September 29, 2004, at approximately 9:30 a.m. Eastern time at an investment conference sponsored by The Research Works, Inc. in New York at the Harvard Club.
Kshitij Mohan, Ph.D., Cytomedix's president and chief executive officer, will provide an overview of the company's unique approach to the treatment of chronic wounds utilizing its propriety AutoloGel(tm) System, as well as the company's progress regarding its intellectual property licensing initiatives.
Earlier this month the company announced it received a favorable ruling from the United States District Court for the District of Massachusetts in its lawsuit against Harvest Technologies for patent infringement of the company's platelet-derived therapies for treating wounds and other damaged tissue.
The company is currently conducting a FDA-approved prospective, randomized, double-blinded controlled study against the standard of care for the treatment of chronic diabetic foot ulcers at over a dozen premier sites throughout the United States.
Cytomedix, Inc. is a biotechnology company specializing in processes and products derived from autologous platelet releasates. The current product offering is the AutoloGel(tm) System, which produces an autologous platelet gel composed of multiple growth factors and fibrin matrix for treatment of chronic wounds. Cytomedix is working with healthcare providers to offer an advanced therapy at the point-of-care in multiple settings. Additional information is available at the company's website at www.cytomedix.com.